Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adherence to Red Reflex and Vision Screening Recommendations: A Deep Dive into Primary Care Implementation Gaps.

medRxiv : the preprint server for health sciences·2026

Same author

Understanding capability, opportunity, and motivation for at-home COVID-19 testing in underserved populations during the pandemic.

Translational behavioral medicine·2026

Same author

Mixed-Method Formative Evaluation and Cultural Adaptation of Digital Health Communication Content and Delivery Promoting Lung Cancer Screening Shared Decision-Making.

Cancer control : journal of the Moffitt Cancer Center·2026

Same author

An exploratory mixed-methods study using the ELICIT framework to identify stakeholder-informed implementation strategies for a population health platform.

BMC health services research·2026

Same author

Enhancing prediction of inpatient deterioration by combining clinical and nurse concern features, with or without temporal clustering.

JAMIA open·2026

Same author

MyLungHealth, a Patient-Facing Education Tool for Lung Cancer Screening: Qualitative User-Centered Design Study.

JMIR formative research·2026

Search research articles

Related Experiment Video

Updated: May 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Developing a prototype system for integrating pharmacogenomics findings into clinical practice.

Casey Lynnette Overby¹, Peter Tarczy-Hornoch, Ira J Kalet

¹Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA 98195, USA ; Department of Biomedical Informatics, Columbia University, New York, NY 10032, USA.

Journal of Personalized Medicine

|June 7, 2013

Summary

This summary is machine-generated.

Pharmacogenomics (PGx) can personalize drug therapy. This study designed a prototype PGx clinical decision support (CDS) system, identifying technical needs for integrating PGx into clinical workflows for better patient care.

Keywords:

clinical decision support systems computerized provider order entry electronic health records knowledge representation personalized medicine pharmacogenomics

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Related Experiment Videos

Last Updated: May 10, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform

Published on: August 17, 2022

Area of Science:

Clinical Pharmacology
Genomics in Medicine
Health Informatics

Background:

Pharmacogenomics (PGx) offers potential for personalized drug therapy, improving efficacy and reducing adverse events.
While factors influencing genomics adoption are known, technical barriers to integrating PGx into clinical practice remain unclear.

Purpose of the Study:

To design and develop a prototype PGx clinical decision support (CDS) system.
To identify technical needs for integrating PGx into existing clinical frameworks and workflows.

Main Methods:

Updated evaluations of PGx knowledge characteristics and CDS capabilities of three local clinical systems.
Assessed alignment with data and functional requirements for PGx CDS.
Developed a prototype PGx CDS system incorporating semi-active and active CDS functionalities.

Main Results:

PGx decision support rules, mainly from FDA labels, focus on drug metabolizing genes and often support post-genetic testing analysis.
Computerized provider order entry (CPOE) is crucial for PGx CDS, with one evaluated system showing better support.
Key technical needs identified include data exchange standards for linking clinical data to PGx knowledge and methods for semi-active CDS implementation.

Conclusions:

Understanding PGx knowledge characteristics and current clinical system capabilities is vital for successful CDS implementation.
The developed prototype and identified technical needs provide principles for designing and implementing CDS to support drug therapy individualization.
This work enhances the understanding of PGx in clinical contexts and guides the development of knowledge resources for clinical care delivery.